BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 71, Issue 5 (May 2019)

Fc Fusion Protein as a Novel Treatment for Myasthenia Gravis Akiyuki Uzawa 1 , Junji Yamashita 2 , Satoshi Kuwabara 1 1Department of Neurology, Graduate School of Medicine, Chiba University 2Research Laboratory, Nihon Pharmaceutical Co. Ltd Keyword: 重症筋無力症 , 融合蛋白 , 革新的治療 , B細胞 , 動物モデル , myasthenia gravis , fusion protein , novel treatment , B cell , animal model pp.525-530
Published Date 2019/5/1
  • Abstract
  • Look Inside
  • Reference


Myasthenia gravis (MG) is an inflammatory disorder caused by autoantibodies against the nicotinic acetylcholine receptor (AChR). New therapeutic options for MG are required because the conventional treatments cannot always achieve long-term remission in MG patients. We developed a fusion protein, AChR-Fc, as a novel therapeutic agent for patients with MG. It is composed of the extracellular domain of human AChR-α1 subunit and human IgG1. AChR-Fc exhibited dual activities: it neutralized anti-AChR antibodies and demonstrated an enhanced cytotoxicity against autoantibody-producing B cells. Therefore, AChR-Fc is a novel biomolecule that can be used in the treatment of patients with MG, and potentially overcomes the disorder.

Copyright © 2019, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
71巻5号 (2019年5月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院